Rani Therapeutics
Founded Year
2012Stage
IPO | IPOTotal Raised
$227MDate of IPO
7/30/2021About Rani Therapeutics
Rani Therapeutics (NASDAQ: RANI) develops a robotic pill for the oral delivery of peptides, proteins, and therapeutic antibodies, which to date can only be delivered through injections. Rani's "robotic" pill is a sophisticated device, enabling it to navigate through the stomach and enter the small intestine. The RaniPill capsule goes through a transformation and aligns itself and injects the drug into the intestinal wall.
Rani Therapeutics Headquarter Location
2051 Ringwood Ave.
San Jose, California, 95131,
United States
408-457-3712
Research containing Rani Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Rani Therapeutics in 1 CB Insights research brief, most recently on Mar 12, 2020.
Mar 12, 2020
100+ Of The Most Well-Funded Medical Device StartupsExpert Collections containing Rani Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Rani Therapeutics is included in 3 Expert Collections, including Medical Devices.
Medical Devices
7,911 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Health IT
7,900 items
Rani Therapeutics Patents
Rani Therapeutics has filed 96 patents.
The 3 most popular patent topics include:
- Digestive system
- Medical equipment
- Drug delivery devices
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/15/2019 | 4/19/2022 | Drug delivery devices, Digestive system, Dosage forms, Pharmacokinetics, Medical equipment | Grant |
Application Date | 5/15/2019 |
|---|---|
Grant Date | 4/19/2022 |
Title | |
Related Topics | Drug delivery devices, Digestive system, Dosage forms, Pharmacokinetics, Medical equipment |
Status | Grant |
Latest Rani Therapeutics News
May 3, 2022
San Jose, California, UNITED STATES SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at two upcoming investor conferences in May: Bank of America 2022 Healthcare Conference. Mr. Imran will present on Tuesday, May 10 at 5:20 PM Pacific Time / 8:20 PM Eastern Time. Mr. Imran will present on Thursday, May 24 at 10:30 AM Pacific Time / 1:30 PM Eastern Time. Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days. Rani Therapeutics Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Rani has developed RaniPill™ capsules, which are a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill™ capsules. For more information, visit ranitherapeutics.com. Investor Contact:
Rani Therapeutics Web Traffic
Rani Therapeutics Rank
You May Also Like
Lyndra Therapeutics aims to improve healthcare outcomes through oral, ultra-long-acting, sustained-release therapies that change how people take medicines. Instead of taking medications daily or more frequently, doses would be administered weekly or monthly, improving medication adherence for better health outcomes and lower healthcare costs. Delivering controlled amounts of medicine would also reduce side effects and improve drug efficacy.
FierceHealthcare delivers healthcare news at the intersection of business and policy. It is based in Washington, DC.
SmartTab is a digital health company that develops targeted, precision prescription drug delivery systems. The company's ingestible wireless remote-controlled drug delivery system delivers drug dosages at precise times to precise locations in the human body.
Progenity (NASDAQ: PROG) is a biotechnology company with a presence in women's health molecular testing and a pipeline of proprietary tests and therapeutic applications. Progenity has a portfolio of technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive prenatal testing (NIPT), all designed to support clinicians in providing excellent patient care.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.